LLY

918.81

+3.95%↑

JNJ

244.43

+0.85%↑

ABBV

217.46

+2.07%↑

NVS

152.81

+1.62%↑

MRK

120.31

+2.08%↑

LLY

918.81

+3.95%↑

JNJ

244.43

+0.85%↑

ABBV

217.46

+2.07%↑

NVS

152.81

+1.62%↑

MRK

120.31

+2.08%↑

LLY

918.81

+3.95%↑

JNJ

244.43

+0.85%↑

ABBV

217.46

+2.07%↑

NVS

152.81

+1.62%↑

MRK

120.31

+2.08%↑

LLY

918.81

+3.95%↑

JNJ

244.43

+0.85%↑

ABBV

217.46

+2.07%↑

NVS

152.81

+1.62%↑

MRK

120.31

+2.08%↑

LLY

918.81

+3.95%↑

JNJ

244.43

+0.85%↑

ABBV

217.46

+2.07%↑

NVS

152.81

+1.62%↑

MRK

120.31

+2.08%↑

Search

Quidel Corp

Fermé

16.41 7.89

Résumé

Variation du prix de l'action

24h

Actuel

Min

15.26

Max

16.56

Chiffres clés

By Trading Economics

Revenu

602M

-131M

Ventes

24M

724M

Marge bénéficiaire

-18.062

Employés

6,500

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+101.51% upside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-248M

961M

Ouverture précédente

8.52

Clôture précédente

16.41

Quidel Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

30 mars 2026, 23:15 UTC

Principaux Événements d'Actualité

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30 mars 2026, 22:36 UTC

Principaux Événements d'Actualité

Australian Government Rules Out Boots on the Ground in the Middle East

30 mars 2026, 22:13 UTC

Acquisitions, Fusions, Rachats

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30 mars 2026, 21:00 UTC

Résultats

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30 mars 2026, 20:15 UTC

Principaux Événements d'Actualité

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30 mars 2026, 23:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 mars 2026, 23:40 UTC

Market Talk

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30 mars 2026, 23:36 UTC

Market Talk

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30 mars 2026, 23:12 UTC

Market Talk

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30 mars 2026, 22:49 UTC

Market Talk

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30 mars 2026, 22:44 UTC

Market Talk

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30 mars 2026, 22:43 UTC

Market Talk

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30 mars 2026, 22:42 UTC

Market Talk

South32 Should Go for Growth, Says New Bull -- Market Talk

30 mars 2026, 22:18 UTC

Market Talk

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30 mars 2026, 22:05 UTC

Market Talk

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30 mars 2026, 21:58 UTC

Acquisitions, Fusions, Rachats

Sun Life Financial Agrees to Buy Bell Partners for $350M

30 mars 2026, 21:39 UTC

Acquisitions, Fusions, Rachats

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30 mars 2026, 21:38 UTC

Acquisitions, Fusions, Rachats

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30 mars 2026, 21:36 UTC

Acquisitions, Fusions, Rachats

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30 mars 2026, 21:33 UTC

Acquisitions, Fusions, Rachats

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30 mars 2026, 21:33 UTC

Acquisitions, Fusions, Rachats

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30 mars 2026, 21:33 UTC

Acquisitions, Fusions, Rachats

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30 mars 2026, 21:33 UTC

Acquisitions, Fusions, Rachats

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30 mars 2026, 21:33 UTC

Acquisitions, Fusions, Rachats

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30 mars 2026, 21:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 mars 2026, 21:25 UTC

Market Talk

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30 mars 2026, 21:03 UTC

Acquisitions, Fusions, Rachats

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30 mars 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30 mars 2026, 20:09 UTC

Résultats

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30 mars 2026, 20:00 UTC

Principaux Événements d'Actualité

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Comparaison

Variation de prix

Quidel Corp prévision

Objectif de Prix

By TipRanks

101.51% hausse

Prévisions sur 12 Mois

Moyen 30.75 USD  101.51%

Haut 38 USD

Bas 25 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

5 ratings

1

Achat

3

Maintien

1

Vente

Éléments financiers

Frais Généraux et Administratifs

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

Bénéfice d'exploitation

$

À Propos Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat